Prevalence of Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a Prevalent Area. | LitMetric
Background: mutation status and prevalence of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) has not yet been reported in Korea. The aim of this study was to investigate the significance of the mutation in the follicular variant of papillary thyroid carcinoma (FVPTC) and to determine the prevalence of NIFTP in mutation-prevalent Korean patients.
Methods: This study retrospectively analyzed 1,417 consecutive patients who underwent total thyroidectomy with routine prophylactic central lymph node dissection for papillary thyroid carcinoma (PTC). mutation analysis was performed routinely using multiplex polymerase chain reaction by applying dual priming oligonucleotide. Clinicopathological characteristics and ultrasonographic findings were compared between mutation-positive and -negative groups for FVPTC. Pathologists reviewed the pathology slides according to consensus diagnostic criteria for the encapsulated FVPTC and NIFTP.
Results: The prevalence of the mutation in all subtypes of PTC was 61.0% (861/1,411). FVPTC presented a mutation rate of 27.3%. The FVPTC patients with mutation were older than those with no mutation ( = 0.021). The prevalence of NIFTP was 0.18% among all PTC patients (2/1,411) and the proportion of NIFTP among FVPTC was 9.1% (2/22).
Conclusion: The mutation is prevalent in Korean patients with FVPTC in a region with high frequency of the mutation and very low prevalence of NIFTP compared with that reported in western studies.
The most prevalent form of thyroid cancer is papillary thyroid carcinoma, of which warthin-like papillary thyroid carcinoma (WLPTC) is an uncommon variant. The symptoms, diagnosis and course of treatment for this subtype of papillary thyroid cancer are comparable to those of the classic variety. It is usually associated with Hashimoto's thyroiditis and is considered to have a favourable prognosis.
Introduction: BRAFV600E mutation (BRAF) is common in papillary thyroid cancer (PTC), and most patients have an excellent outcome. However, a TERT-promoter mutation (pTERT) in the presence of BRAF (BRAFpTERT) has been demonstrated to confer a more aggressive behavior to PTC. Lymphocytic infiltration is often present in PTC.
Background: This study aimed to evaluate the safety, efficacy, and oncologic outcomes of thermal ablation techniques, including radiofrequency, laser, and microwave ablation, in treating primary thyroid cancer compared with surgical resection.
Method: We conducted a systematic review and network meta-analysis, which included 21 comparative studies and 40 noncomparative studies.
Results: The three thermal ablation techniques showed significant superiority over surgical resection in terms of operative time, pain, cost, quality of life, and complications.
Objective: Resistance to thyroid hormone beta (RTHβ) is a rare disorder characterized by a fairly heterogeneous clinical presentation due to varying degrees of tissue response to thyroid hormone. The study aimed to evaluate the clinical, laboratory features and genotype-phenotype relationship of Turkish patients with RTHβ.
Methods: Patients who underwent a THRB gene analysis between September 2019 and September 2023 were retrospectively reviewed.
Objectives: Papillary thyroid cancer (PTC) is the most frequent subtype of thyroid cancer with overall favorable survival. Currently, little is known about the PTC experience within the United States (U.S.
